ibuprofen topical (TIB200) / Futura Medical - LARVOL DELTA

Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC). (PubMed, Clin Cancer Res) - "Among patients with mTNBC treated with 0-1 prior lines, adavosertib combined with cisplatin missed the prespecified ORR cutoff of >30%. The finding of immune-infiltrated tumors in patients with clinical benefit warrants validation."

Clinical • Journal • Breast Cancer • Infectious Disease • Oncology • Septic Shock • Solid Tumor • Triple Negative Breast Cancer

Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model (clinicaltrials.gov) - P1; N=60; Completed; Sponsor: Futura Medical Developments Ltd.; N=220 ➔ 60

Clinical • Enrollment change • Pain

Comparison of ibuprofen and piroxicam gel in the treatment of trauma pain: A randomized double-blind trial of geriatric population. (PubMed, Am J Emerg Med) - "Ibuprofen gel, which is a safe treatment option for geriatric patients, is more clinically effective than piroxicam gel. Response to Reviewers."

Clinical • Journal • Geriatric Disorders • Mood Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model (clinicaltrials.gov) - P1; N=220; Completed; Sponsor: Futura Medical Developments Ltd.; N=60 ➔ 220

Clinical • Enrollment change • Pain

Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model (clinicaltrials.gov) - P1; N=60; Completed; Sponsor: Futura Medical Developments Ltd.

New P1 trial • Biosimilar • Immunology • Inflammation • Pain • Reperfusion Injury

Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2− Breast Cancer (CAPItello-291) (clinicaltrialsregister.eu) - P3; N=700; Ongoing; Sponsor: AstraZeneca AB

Clinical • New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PGR

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors. (PubMed, Cancer Chemother Pharmacol) - "Ipatasertib, at the monotherapy MTD of 600 mg/day and MAD of 400 mg/day in combination with abiraterone and prednisolone, was safe and tolerable in Japanese patients with solid tumors."

Clinical • Combination therapy • Journal • P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

Randomized Phase II Study of Akt Blockade With or Without Ipatasertib in Abiraterone-Treated Patients With Metastatic Prostate Cancer With and Without PTEN Loss. (PubMed, Clin Cancer Res) - "In mCRPC, combined blockade with abiraterone and ipatasertib showed superior antitumor activity to abiraterone alone, especially in patients with PTEN-loss tumors."

Clinical • Combination therapy • Journal • P2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

A Study of Ipatasertib in Combination with Atezolizumab and Paclitaxel as a Treatment for Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer ESTUDIO DE IPATASERTIB EN COMBINACIÓN CON ATEZOLIZUMAB Y PACLITAXEL COMO TRATAMIENTO PARA PACIENTES CON CÁNCER DE MAMA TRIPLE NEGATIVO NO RESECABLE O METASTÁSICO (clinicaltrialsregister.eu) - P3; N=1150; Ongoing; Sponsor: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd

Clinical • Combination therapy • New P3 trial

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (clinicaltrialsregister.eu) - P3; N=800; Ongoing; Sponsor: AstraZeneca AB

Clinical • New P3 trial